{
    "id": 562,
    "fullName": "TP53 P72R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TP53 P72R lies within the CCAR2, HRMT1L2, and WWOX-interacting regions of the Tp53 protein (UniProt.org). P72R is a common Tp53 polymorphism, but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PMID: 19165225, PubMed, Oct 2019).",
            "references": [
                {
                    "id": 4002,
                    "pubMedId": 19165225,
                    "title": "p53 polymorphisms: cancer implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19165225"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "P72R",
    "createDate": "05/14/2014",
    "updateDate": "10/15/2019",
    "referenceTranscriptCoordinates": {
        "id": 95161,
        "transcript": "NM_000546",
        "gDna": "chr17:g.7676154G>C",
        "cDna": "c.215C>G",
        "protein": "p.P72R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 925,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and Platinol (cisplatin) (PMID: 18618574).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1406,
                "therapyName": "Cisplatin + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 603,
                    "pubMedId": 18618574,
                    "title": "Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18618574"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 845,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1472,
                "therapyName": "Doxorubicin + Ifosfamide",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 485,
                    "pubMedId": 23165797,
                    "title": "Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23165797"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 325,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1007,
                "therapyName": "Daunoxome",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13,
                    "pubMedId": 16243804,
                    "title": "p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16243804"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 329,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1008,
                "therapyName": "Pegylated liposomal-doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13,
                    "pubMedId": 16243804,
                    "title": "p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16243804"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 324,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1006,
                "therapyName": "Daunorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13,
                    "pubMedId": 16243804,
                    "title": "p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16243804"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 341,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1013,
                "therapyName": "Epirubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 67,
                    "pubMedId": 22903472,
                    "title": "Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22903472"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 330,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804).",
            "molecularProfile": {
                "id": 621,
                "profileName": "TP53 P72R"
            },
            "therapy": {
                "id": 1706,
                "therapyName": "Cyclophosphamide + Doxorubicin + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 60076,
                "name": "estrogen-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13,
                    "pubMedId": 16243804,
                    "title": "p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16243804"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 745,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661).",
            "molecularProfile": {
                "id": 1050,
                "profileName": "TP53 P72R TP53 Y220C"
            },
            "therapy": {
                "id": 1087,
                "therapyName": "Cyclophosphamide + Epirubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 446,
                    "pubMedId": 17388661,
                    "title": "Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17388661"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 621,
            "profileName": "TP53 P72R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1050,
            "profileName": "TP53 P72R TP53 Y220C",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 95163,
            "transcript": "NM_001126114",
            "gDna": "chr17:g.7676154G>C",
            "cDna": "c.215C>G",
            "protein": "p.P72R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95160,
            "transcript": "NM_001126112",
            "gDna": "chr17:g.7676154G>C",
            "cDna": "c.215C>G",
            "protein": "p.P72R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95162,
            "transcript": "NM_001126113",
            "gDna": "chr17:g.7676154G>C",
            "cDna": "c.215C>G",
            "protein": "p.P72R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95161,
            "transcript": "NM_000546",
            "gDna": "chr17:g.7676154G>C",
            "cDna": "c.215C>G",
            "protein": "p.P72R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}